Purpose:To aid comparison of the performance of patient specific QA (PSQA) programs across centersMethods:Up to 414 VMAT/IMRT plans from various treatment sites (most commonly prostate, prostate bed, lung and lung SBRT) from a year period of ArcCHECK measurements were analysed using a range of acceptance criteria including variations of the following parameters: Gamma or DTA, Relative (RD) or Absolute Dose (AD), Van Dyk and Threshold (TH). A total of 24 different criteria were selected in the SNC Patient software to evaluate each plan and determine all reportable passing rates (PR).Results:The average passing rate (Rateavg) for all plans using all combinations of criteria ranges from about 93% using “3% Dose, 2mm DTA, AD, 10% TH, no Van dyk” criteria to nearly 100% using “Gamma with 3%Dose, 3mm DTA, RD, 10% TH, no Van dyk”. The 90th percentile of passing rates was also quantified and ranges from about 85% to nearly 100%. When analysed by site, prostate and prostate bed plans show the highest Rateavg, while SBRT lung plans shows the widest spread of rates. As expected, Rateavg decreases as the selection of Gamma changes to DTA, AD changes to RD, and “Van dyk” is turned off. Additionally, Rateavg decreases as TH percent selection decreases.Conclusions:The results enable comparisons of PR considering criteria stringency hence enabling better comparison of PSQA programs across centres. The study allows better understanding on how the parameters affect the reported PR and the level of stringency from all combinations.